Core Insights - WuXi Biologics has received the AAA ESG rating from MSCI for the third consecutive year, highlighting its commitment to sustainability and strong ESG performance [1][2]. Company Performance - The AAA rating places WuXi Biologics among an elite group of companies recognized for outstanding ESG performance, particularly in climate change, product safety, human capital development, and corporate governance [2]. - The company has been actively engaged with the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative, aligning its efforts with the United Nations Sustainable Development Goals [4]. Recognition and Awards - WuXi Biologics has received multiple accolades for its sustainability efforts, including an EcoVadis Platinum Medal, inclusion in the Dow Jones Sustainability Indices, and recognition as a top-rated company by Sustainalytics for five consecutive years [5]. - The company has also been rated as Prime by ISS ESG Corporate Rating and is a constituent of the FTSE4Good Index Series [5]. Operational Overview - WuXi Biologics employs over 12,000 skilled employees across various countries, including China, the United States, Ireland, Germany, and Singapore, providing efficient and cost-effective biologics solutions [8]. - As of June 30, 2025, the company is supporting 864 integrated client projects, with 24 in commercial manufacturing [8]. Commitment to Sustainability - The company views sustainability as a cornerstone of long-term business growth and continuously drives green technology innovations to offer advanced Green CRDMO solutions [9]. - WuXi Biologics collaborates with stakeholders to foster positive social and environmental impacts, promoting responsible practices throughout the value chain [9].

Core Insights - WuXi Biologics has been recognized on the CDP's A List for Supplier Engagement Assessment, highlighting its leadership in climate-related supply chain engagement [1][2] - The company has achieved a 30% reduction in GHG emissions intensity (Scope 1 and Scope 2) in 2024 compared to the base year 2020, with a goal of net-zero emissions by 2050 [3][4] - WuXi Biologics has received multiple recognitions for its sustainability efforts, including an MSCI AAA Rating and inclusion in the Dow Jones Sustainability Indices [4][9] Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics [6][8] - The company employs over 12,000 skilled professionals across various countries, supporting 817 integrated client projects as of December 31, 2024 [8] - Sustainability is a cornerstone of WuXi Biologics' long-term business strategy, focusing on green technology innovations and responsible practices [9] Environmental Commitment - WuXi Biologics is committed to the Science Based Target initiative (SBTi) and has established measurable targets for climate change [3] - The company actively engages with suppliers to enhance sustainable supply chain management and Scope 3 emissions reporting [3][4] - WuXi Biologics has been recognized for its water security efforts, being included in CDP's Water Security A List [2][4] Recognition and Ratings - The company has received leadership-level scores from CDP for two consecutive years, reflecting its commitment to climate change initiatives [2][4] - WuXi Biologics has been awarded an EcoVadis Platinum Medal and recognized as a top-rated company by Sustainalytics for five consecutive years [4][9] - The company is a participant in the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative, further emphasizing its dedication to sustainability [4]